Longeveron
Life Science & Technology Park
1951 NW 7th Avenue, Suite 300
Miami
Florida
33136
United States
Tel: 305-342-9590
Website: http://www.longeveron.com/
About Longeveron
Longeveron is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility.YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CSO: Joshua M. Hare, M.D.
138 articles about Longeveron
-
Longeveron Announces 1-for-10 Reverse Stock Split - March 19, 2024
3/19/2024
Longeveron Inc. announced that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share .
-
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
2/27/2024
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the year ended December 31, 2023 and provided a corporate update.
-
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
2/21/2024
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on February 27, 2024.
-
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
1/29/2024
Longeveron Inc. today announces it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs), the technology behind its lead investigational product Lomecel-B TM.
-
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/21/2023
Longeveron Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.
-
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
12/20/2023
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) today announces additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.
-
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association
11/11/2023
Longeveron Inc. announced that extended long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome is being presented as a poster at the annual Scientific Sessions of the American Heart Association, being held in Philadelphia, PA on November 11-13, 2023.
-
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
11/10/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a corporate update.
-
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
11/3/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial results prior to the market open on Friday November 10, 2023.
-
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s
10/24/2023
Longeveron Inc. today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.
-
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10/12/2023
Longeveron Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock.
-
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
10/5/2023
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) today announced positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.
-
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
9/7/2023
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”) announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation as a poster at the upcoming meeting of the American Heart Association (AHA).
-
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
9/5/2023
Longeveron Inc. announced today that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023.
-
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
8/29/2023
Longeveron Inc. announced that the Company’s management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.
-
Longeveron Rights Offering Subscription Period Begins
8/22/2023
Longeveron Inc. announced that the subscription period for its previously announced rights offering has begun.
-
Longeveron Rights Offering Declared Effective and Calendar Finalized - August 16, 2023
8/16/2023
Longeveron Inc. announced that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar.
-
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
8/14/2023
Longeveron Inc., a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET.
-
Longeveron Announces Pricing for Rights Offering and Expected Calendar
8/14/2023
Longeveron Inc. announced that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of its Class A common stock, Class B common stock and warrants to purchase its Class A common stock.
-
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
8/11/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update.